Tissue Regenix Group (LSE:TRX) Scaled Net Operating Assets: 0.79 (As of Jun. 2025)


What is Tissue Regenix Group Scaled Net Operating Assets?

Tissue Regenix Group LSE:TRX Scaled Net Operating Assets is 0.79 as of Jun. 2025. The stock has 5 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tissue Regenix Group's operating assets for the quarter that ended in Jun. 2025 was £33.99 Mil. Tissue Regenix Group's operating liabilities for the quarter that ended in Jun. 2025 was £5.58 Mil. Tissue Regenix Group's Total Assets for the quarter that ended in Dec. 2024 was £35.87 Mil. Therefore, Tissue Regenix Group's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2025 was 0.79.

Tissue Regenix Group Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group Scaled Net Operating Assets Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.79 0.68 0.80 0.71 0.87

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.76 0.84 0.84 0.79

LSE:TRX vs VRTX, REGN, ALNY: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Tissue Regenix Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's Scaled Net Operating Assets falls into.


Tissue Regenix Group Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tissue Regenix Group's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2024 )
=(Operating Assets (A: Dec. 2024 )-Operating Liabilities (A: Dec. 2024 ))/Total Assets (A: Dec. 2023 )
=(34.39-4.607)/34.162
=0.87

where

Operating Assets(A: Dec. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=35.869 - 1.479
=34.39

Operating Liabilities(A: Dec. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=12.885 - 7.795 - 0.483
=4.607

Tissue Regenix Group's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2025 )
=(Operating Assets (Q: Jun. 2025 )-Operating Liabilities (Q: Jun. 2025 ))/Total Assets (Q: Dec. 2024 )
=(33.986-5.576)/35.869
=0.79

where

Operating Assets(Q: Jun. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=34.778 - 0.792
=33.986

Operating Liabilities(Q: Jun. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13.682 - 7.687 - 0.419
=5.576

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.79 mean?
Tissue Regenix Group (LSE:TRX) has a Scaled Net Operating Assets of 0.79 as of Jun. 2025. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's Scaled Net Operating Assets too high?
Tissue Regenix Group's current Scaled Net Operating Assets is 0.79.
How does Tissue Regenix Group's Scaled Net Operating Assets compare to VRTX and REGN?
Tissue Regenix Group's Scaled Net Operating Assets of 0.79 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current Scaled Net Operating Assets is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current Scaled Net Operating Assets of 0.79. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current Scaled Net Operating Assets is 0.79. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current Scaled Net Operating Assets is 0.79 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.